One such tumor penetrating peptide, iRGD (sequence: disulfide-cyclized CRGDKGPDC) [221,222,223,225], is undergoing clinical testing for precision delivery of paclitaxel albumin nanoparticles (Abraxane) and gemcitabine to pancreatic cancer lesions (ClinicalTrials.gov Identifier: NCT03517176, “CEND-1 in combination with Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer”). This evidence concerns the gene ALB and pancreatic neoplasm.